Adelmidrol

Adelmidrol is an anti-inflammatory ethanolamide derivative of azelaic acid.

Adelmidrol
Names
IUPAC name
N,N′-Bis(2-hydroxyethyl)nonanediamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
Properties
C13H26N2O4
Molar mass 274.361 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Description

Adelmidrol is the semisynthetic diethanolamide derivative of azelaic acid,[1] and has a symmetrical chemical structure. It classed as an amide, and is similar to palmitoylethanolamide, the parent molecule in the ALIAmide class of drugs.[2] ALIAmides are group of fatty acid derivatives with cannabimimetic properties,[1] which have antiinflammatory and analgesic effects and are thought to act by reducing mast cell activation.[2]

It is used extensively in Italy in veterinary medicine to treat skin inflammation. In 2015, it was found the compound also exerts anti-inflammatory action given systemically in 10 mg per kg bodyweight.[3]

In pet animals and in atopic eczema

Adelmidrol has been shown to negatively control the behavior of canine skin MCs during pathophysiological conditions (i.e. healing of experimental wounds). In particular, a statistically significant increase of intracytoplasmatic granular content of dermal MCs was shown in adelmidrol (2%)-treated wounds compared to control, thus suggesting the compound is effectively able to down-modulate skin MC degranulation in dogs.[4]

Chronic gingiva inflammation can be a difficult to treat medical problem in dogs. A similar anti-inflammatory effect was observed in these dogs, treated with a gel to reduce gingival inflammation. Twenty dogs were randomised to the adelmidrol gel and placebo. After 30 and 45 days, the dogs using the adelmidrol gel had significantly less inflammation of the gingiva.[5]

Furthermore, the local application of adelmidrol has been recently confirmed to reduce MC responses during chronic experimental inflammation, as shown by the significant decrease of mediators selectively expressed by MCs and involved in skin inflammation, such as chymase.[2]

Adelmidrol seems suitable for topical application, as it exhibits both hydrophilic and lipophilic features, which help it to be absorbed into the skin, as the epidermis is composed of alternating lipophilic and hydrophilic layers.[1]

A 4-week topical treatment with adelmidrol 2% emulsion in children affected by mild atopic dermatitis resulted in complete resolution in 80% of cases, with no side effects and no relapses at 8-week follow up.[6]

gollark: ++magic py```pythonembed = discord.Embed(title="Title", description="Desc", color=0x00ff0f).set_thumbnail(url="https://media.discordapp.net/attachments/457999277311131649/772461444646174740/ferris.png")await ctx.send(embed=embed)```
gollark: ++magic py```pythonembed = discord.Embed(title="Title", description="Desc", color=0x00ff0f).set_thumbnail(url="https://media.discordapp.net/attachments/457999277311131649/772461444646174740/ferris.png", name="apiform")await ctx.send(embed=embed)```
gollark: ++magic py```pythonembed = discord.Embed(title="Title", description="Desc", color=0x00ff0f).set_author(url="https://media.discordapp.net/attachments/457999277311131649/772461444646174740/ferris.png", name="apiform")await ctx.send(embed=embed)```
gollark: I didn't actually program the achievement in yet.
gollark: ℍ𝕖𝕒𝕧𝕡𝕠𝕠𝕥#5118

References
  1. Cerrato, Santiago; Brazis, Pilar; della Valle, Maria Federica; Miolo, Alda; Puigdemont, Anna (2012). "Inhibitory effect of topical Adelmidrol on antigen-induced skin wheal and mast cell behavior in a canine model of allergic dermatitis". BMC Veterinary Research. 8 (1): 230. doi:10.1186/1746-6148-8-230. PMC 3540011. PMID 23181761.
  2. De Filippis, Daniele; D'Amico, Alessandra; Cinelli, Maria Pia; Esposito, Giuseppe; Di Marzo, Vincenzo; Iuvone, Teresa (1 July 2009). "Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats". Journal of Cellular and Molecular Medicine. 13 (6): 1086–1095. doi:10.1111/j.1582-4934.2008.00353.x. PMC 4496105. PMID 18429935.
  3. Cordaro, M; Impellizzeri, D; Gugliandolo, E; Siracusa, R; Crupi, R; Esposito, E; Cuzzocrea, S (2016). "Adelmidrol, a Palmitoylethanolamide Analogue, as a New Pharmacological Treatment for the Management of Inflammatory Bowel Disease". Molecular Pharmacology. 90 (5): 549–561. doi:10.1124/mol.116.105668. PMID 27625036.
  4. Abramo, F; Salluzzi, D; Leotta, R; Auxilia, S; Noli, C; Miolo, A; Mantis, P; Lloyd, D. H (2008). "Mast cell morphometry and densitometry in experimental skin wounds treated with a gel containing adelmidrol: A placebo controlled study". Wounds : A Compendium of Clinical Research and Practice. 20 (6): 149–57. PMID 25942520.
  5. Bonello, D.; Squarzoni, P. (March 2008). "Effect of a Mucoadhesive Gel and Dental Scaling on Gingivitis in Dogs". Journal of Veterinary Dentistry. 25 (1): 28–32. doi:10.1177/089875640802500108. PMID 18512623.
  6. Pulvirenti, N; Nasca, M. R; Micali, G (2007). "Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: A pilot study". Acta Dermatovenerologica Croatica : Adc. 15 (2): 80–3. PMID 17631786.
  •  This article incorporates text by Santiago Cerrato, Pilar Brazis, Maria Federica della Valle, Alda Miolo and Anna Puigdemont available under the CC BY 2.0 license.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.